Repligen (RGEN)CFO sold ~$106K

~$106K

Approx. value · 733 sh @ $145.00

19K

Holds after · shares reported

Traded

Jun 25, 2026

Filed

Jun 27, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. May 5, 2026Company filing · Form 8-K · ResultsReported its results
2. May 28, 2026Federal contract · $175K obligatedDepartment of Health and Human Services awarded REPLIGEN CORP: $175K obligated to date
3. Jun 25, 2026 · this disclosureInsiderCFO sold ~$106K of RGEN shares in the open market

What came next

1. Jul 16, 2026InsiderCFO sold ~$80K of RGEN shares in the open market
2. Jul 21, 2026Company filing · Form 8-K · Material agreement, ResultsSigned an important agreement, and reported its results (and 2 more items)
3. Jul 28, 2026Company filing · Form 8-K · ResultsReported its results
4. Aug 20, 2026InsiderCEO sold ~$977K of RGEN shares in the open market
5. Sep 1, 2026Federal contract · $169K obligatedDepartment of Agriculture awarded REPLIGEN CORP: $169K obligated to date
6. Sep 4, 2026InsiderCEO sold ~$504K of RGEN shares in the open market
7. Sep 10, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On September 10, 2026, Karen A. Dawes notified Repligen Corporation (“Repligen”) that she will be retiring from the Repligen Board of Directors (the “Board”) after over twenty years of distinguished service to Repligen, effective as of September 30, 2026.”
8. Sep 21, 2026InsiderCEO sold ~$977K of RGEN shares in the open market
9. Sep 24, 2026Insider · 1 personInsiders: 2 sales (~$2.5M)
10. Oct 5, 2026Insider · 1 personInsiders: 2 sales (~$1.0M)
11. Oct 6, 2026Company filing · Form 8-K · Acquisition or sale, Reg FDCompleted buying or selling a business or assets, and shared information with investors“The information set forth in the “Explanatory Note” of this Current Report on Form 8-K is incorporated by reference into this”
12. Oct 7, 20265% stakeFMR LLC reported a passive stake (13G) of 13.0%

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Repligen

For Repligen, OQRO holds 10 insider filings (SEC Form 4 or Form 144), 15 fund holdings reports (13F) and 1 federal contract award dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its RGEN page.

Other recent filings by Jason K Garland, CFO

• SEC Form 4 at Repligen (RGEN)Jul 18, 2026

The full history of Jason K Garland, CFO is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Repligen

• SEC Form 4Oct 6, 2026
• SEC Form 4Oct 6, 2026
• SEC Form 144Oct 5, 2026
• SEC Form 144Oct 5, 2026
• SEC Form 4Sep 26, 2026
• SEC Form 4Sep 26, 2026

Everything OQRO holds on this company is on its RGEN page.